T
Tomasz Kucharczyk
Researcher at Medical University of Lublin
Publications - 34
Citations - 312
Tomasz Kucharczyk is an academic researcher from Medical University of Lublin. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 9, co-authored 28 publications receiving 244 citations.
Papers
More filters
Journal ArticleDOI
Septin 9 promoter region methylation in free circulating DNA—potential role in noninvasive diagnosis of lung cancer: preliminary report
TL;DR: The aim of the study was to define the frequency of SEPT9 promoter methylation in lung cancer patients and evaluation of usefulness of this marker in early diagnostic of lung cancer.
Journal ArticleDOI
Polymorphisms in TS, MTHFR and ERCC1 genes as predictive markers in first-line platinum and pemetrexed therapy in NSCLC patients
Paweł Krawczyk,Tomasz Kucharczyk,Dariusz M. Kowalski,Tomasz Powrózek,Rodryg Ramlau,Ewa Kalinka-Warzocha,Kinga Winiarczyk,Magdalena Knetki-Wróblewska,Kamila Wojas-Krawczyk,Katarzyna Kałakucka,Wojciech Dyszkiewicz,Maciej Krzakowski,Janusz Milanowski +12 more
TL;DR: Polymorphic tandem repeat sequence (2R, 3R) in the enhancer region of TS gene and G>C SNP within the second repeat of 3R allele seem to be important for the effectiveness of platinum and pemetrexed in first-line chemotherapy.
Journal ArticleDOI
Predictive value of ERCC1 and RRM1 gene single-nucleotide polymorphisms for first-line platinum- and gemcitabine-based chemotherapy in non-small cell lung cancer patients
Radosław Mlak,Paweł Krawczyk,Rodryg Ramlau,Ewa Kalinka-Warzocha,Maja Wasylecka-Morawiec,Kamila Wojas-Krawczyk,Tomasz Kucharczyk,Iwona Homa,Piotr Kozioł,Marzanna Ciesielka,Dorota Chudziak,Janusz Milanowski +11 more
TL;DR: The analysis of RRM1 (-37C>A) more than ERCC1 (19007C>T) polymorphism may be a promising tool in the qualification of NSCLC patients for chemotherapy containing platinum compounds and gemcitabine.
Journal ArticleDOI
Predictive value of ERCC1 single-nucleotide polymorphism in patients receiving platinum-based chemotherapy for locally-advanced and advanced non-small cell lung cancer--a pilot study.
Paweł Krawczyk,Kamila Wojas-Krawczyk,Radosław Mlak,Tomasz Kucharczyk,Beata Biernacka,Janusz Milanowski +5 more
TL;DR: Rare TT genotype of ERCC1 19007 T>C polymorphism could predict poor response and shortening of progression free survival in NSCLC patients treated with platinum-based I-line chemotherapy.
Journal ArticleDOI
The qualification of docetaxel or erlotinib for second-line therapy should be based on clinical and molecular predictive factors.
Paweł Krawczyk,Dariusz M. Kowalski,Kamila Wojas-Krawczyk,Radosław Mlak,Piotr Jaśkiewicz,Tomasz Kucharczyk,Kinga Winiarczyk,Maciej Krzakowski,Janusz Milanowski +8 more
TL;DR: Elotinib and docetaxel show similar efficacy in the treatment of NSCLC and the application of predictive factors may facilitate qualification for second-line treatment with both drugs.